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ABSTRACT
An additional chromatographic peak was observed in
plasma samples of patients receiving NX 211, a liposomal
formulation of the topoisomerase I inhibitor lurtotecan. We
have isolated and purified this product by sequential solid-
phase extractions, and we report its structure and cytotox-
icity relative to lurtotecan and related agents. Nuclear mag-
netic resonance data indicate that cleavage of the piperazino
moiety occurred at the N-C bond of the B-ring, yielding
7-methyl-10,11-ethylenedioxy-20(S)-camptothecin (MEC).
Tests of the growth inhibition potential of MEC in seven
human tumor cell lines showed that the compound was
approximately 2–18-fold more cytotoxic than lurtotecan,
topotecan, and 7-ethyl-10-hydroxy-20(S)-camptothecin (SN-
38). Subsequently, we found that MEC was the product of
rapid photolysis of lurtotecan, with the rate of degradation
inversely proportional to NX 211 concentrations, and
greatly depends on light intensity. Furthermore, MEC con-
centrations were found to increase significantly in plasma
samples exposed to laboratory light but not in blood. MEC
was not produced from NX 211 in the presence of human
liver microsomes, suggesting that it is not a product of
cytochrome P-450 metabolism. Using a validated analytical
method, trace levels of MEC were quantitated in blood
samples of two patients. These observations confirm that the
precautions for protection from light currently specified for
preparation and administration of NX 211 dose solutions are
critical. Procedures to minimize formation of MEC, by the
use of amber vials for NX 211 and by preparation of dilu-
tions immediately before clinical use in a fashion completely
protected from light, are now being routinely implemented.
INTRODUCTION
The currently known analogues of camptothecin, a cyto-
toxic plant alkaloid from Camptotheca acuminata, share a basic
pentacyclic structure with a chiral center located at C20 in the
terminal E-ring (Fig. 1). Extensive studies on the synthesis of
these derivatives and the development of structure-activity re-
lationships have been carried out over the last several years, and
some important general relationships have emerged (1). One of
the principal chemical features of this class of agents is the
presence of a lactone functionality in the E-ring, which is not
only essential for antitumor activity but also confers a degree of
instability to these agents in aqueous solutions (2). The camp-
tothecins can undergo a pH-dependent reversible interconver-
sion between this lactone form and a ring-opened carboxylate
(or hydroxy acid) form, of which only the former exerts the
characteristic topoisomerase I-inhibitory activity. In the search
for more potent camptothecin analogues, the synthetic prepara-
tion of hexacyclic derivatives has been described, and two
representative agents of this class, lurtotecan and exatecan
mesylate (DX-8951f), are currently undergoing clinical evalua-
tion (3, 4). The former is a water-soluble derivative with a
dioxalane moiety between C10 and C11 (5) and has been
evaluated clinically in various Phase I and Phase II trials using
a 30-min i.v. infusion given daily for 5 days or as a 72-h
continuous i.v. infusion (6–8). Alternative strategies of lurtote-
can administration are currently being developed, including a
new liposomal formulation, NX 211, to further stabilize the
lactone moiety and induce sustained drug levels that may be
required to maximize antitumor activity (9, 10). We previously
reported the presence of an unidentified compound in the
plasma of patients treated with NX 211 as well as in control
samples with the liposomal product added (11). Because the
native fluorescence intensity of the parent drug (i.e., lurtotecan)
was shown previously to be sensitive to UV-light exposure (254
nm) and the fact that the peak height of the newly generated
compound was correlated with the lurtotecan concentration, we
suspected photodegradation of lurtotecan to produce an addi-
tional species. In the current study, we have isolated this un-
known compound by using HPLC2 coupled with fluorometric
detection, followed by NMR analysis of the purified fraction.
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Next, the properties of this compound in terms of cell growth
inhibition relative to related analogues were examined in addi-
tion to the kinetics of lurtotecan photolysis in various aqueous
and biological solutions.
MATERIALS AND METHODS
Chemicals. Lurtotecan and NX 211 were supplied by OSI
Pharmaceuticals, Inc. (San Dimas, CA). Topotecan was a gift from
Smith-Kline Beecham Pharmaceuticals (King of Prussia, PA), and
SN-38 was supplied by Aventis (Alfortville, France). RPMI 1640,
penicillin, streptomycin, and L-glutamine were purchased from Life
Technologies, Inc. (Gaithersburg, MD), and FCS was delivered by
Hyclone (Logan, UT). ACN and MeOH, both HPLC-grade, were
obtained from Biosolve (Valkenswaard, the Netherlands), and
DMSO was from Rathburn (Walkerburn, United Kingdom). Baker
(Deventer, the Netherlands) delivered trichloroacetic acid, acetic
acid (99–100%), PCA (70%), and HCl (36–38%), and ammonium
acetate was from Roth (Karlsruhe, Germany). Sulforhodamine B
and NADPH were obtained from Sigma Chemical Co. (St. Louis,
MO). PBS, obtained from Oxoid and supplied by Boom (Meppel,
the Netherlands), consisted of tablets containing sodium chloride
(8.0 g/l), potassium chloride (0.2 g/l), disodium hydrogen phos-
phate (1.15 g/l), and potassium dihydrogen phosphate (0.2 g/l),
each dissolved in 100 ml of purified water. All water used in the
study was filtered and deionized with a Milli-Q-UF system
(Millipore, Milford, MA).
Isolation and Purification. MEC was prepared by ex-
posure of 17 mg of the lactone form of LRT in a total volume
of 40 ml of DMSO-0.1 M ammonium acetate (pH 5.5; 1:4, v/v)
to 254-nm UV light in a Beam-Boost photochemical reactor unit
(ICT-ASS-Chem, Bad Homburg, Germany) for 5 min. After
irradiation, the sample was acidified with 400 l of PCA and
applied onto four C18 solid-phase extraction cartridges (Applied
Separations, Allentown, PA). Subsequently, the cartridges were
washed three times with 1 ml of 25 mM ammonium acetate (pH
3.0), followed by three times with 1-ml volumes of a mixture of
25 mM ammonium acetate (pH 3.0):MeOH (6:4, v/v). The
columns were eluted with three 1-ml volumes of 25 mM ammo-
nium acetate (pH 3.0):MeOH (1:9, v/v), followed by three 1-ml
volumes of MeOH. The eluate was dried at 60°C under nitrogen
until 1 ml was left over, which resulted in a precipitate in the
sample. To resuspend the precipitate, the sample was diluted
with 10% PCA:ACN:PBS (2:1:6, v/v/v) to 12 ml, and 200-l
portions of this mixture were injected onto the HPLC system as
described previously (11) with the flow rate set at 3.75 ml. The
peaks with a retention time of 17 min were collected, in a total
volume of 1 liter, which was acidified with 10 ml of PCA and
filled with water up to 2 liters. Further purification was achieved
on C18 solid-phase extraction cartridges, which were washed
three times with 1 ml of water, followed by elution with 5
volumes of 1 ml of MeOH. The eluate fractions were collected
and lyophilized using a FDC206 freeze-drying chamber (Savant,
Farmingdale, NY) to obtain the pure compound for chemical
and biological characterization.
Structural Analysis. The isolated powder was character-
ized by 1H NMR spectrum, measured on a Bruker AM-300 (300
MHz, FT) spectrometer. Chemical shift values are reported as 
values in ppm using DMSO-D6 (2.5 ppm) as a standard.
Cytotoxicity Assays. The human colon carcinoma WiDr,
the ovarian adenocarcinoma IGROV-1, the M-19 melanoma, the
H226 lung cancer, the renal cancer cell A498, and the MCF7
and EVSAT breast cancer cell lines were grown and maintained
in RPMI 1640. Cells were kept in continuous logarithmic
growth at 37°C in a humidified atmosphere in 5% CO2 in media
supplemented with 10% (w/v) heat-inactivated FCS, 100
units/ml of penicillin, 100 g/ml of streptomycin, and 2 mM
L-glutamine. Exponentially grown cells were trypsinized and
plated (200 l with 2000 cells/well) in 96-well culture plates
(Costar Corp., Cambridge, MA) 48 h before drug exposure. The
stock solution of MEC was diluted in a mixture of DMSO:HCl
(98:2, v/v), resulting in an 18 M concentration, whereas lurto-
tecan, topotecan, and SN-38 were dissolved separately in
DMSO:HCl (98:2, v/v) to obtain 180 M concentrations. Before
addition to the cells, the solutions were diluted 20-fold in culture
medium, resulting in 0.90 M concentrations of MEC and 9.0
M lurtotecan, topotecan, and SN-38. A 100-l volume of these
solutions was added to the cells, followed by 3-fold serial
dilutions in the 96-well plate. Subsequently, the plates were
incubated for a period of 5 days. For comparative purposes,
MEC, lurtotecan, topotecan, and SN-38 were evaluated in par-
allel in all experiments. After fixation with 10% (w/v) aqueous
trichloroacetic acid, inhibition of cell proliferation was assessed
using sulforhodamine B staining as described previously (12),
with minor modifications (13). Each compound was tested in
quadruplicate in three independent experiments. Cell survival
was plotted relative to controls incubated in medium in the
absence of the drugs. IC50s were calculated after fitting the
individual curves to a Hill function using the software package
Siphar version 4.0 (Inna Phase, Philadelphia, PA).
Analytical Methods. Total lurtotecan concentrations in
human whole blood were determined using a validated HPLC
method (Ref. 10). In brief, aliquots of 50 l of heparinized
whole blood were pretreated with 500 l of 5% (w/v) aqueous
PCA:ACN (5:1, v/v), followed by vigorous vortex-mixing for
30 min. Subsequently, the samples were centrifuged for 5 min at
23,000  g. The HPLC system was identical to that described
previously for the determination of lurtotecan concentrations in
urine (11), with the flow rate set at 1.25 ml/min. For determi-
nation of MEC in whole blood samples, the HPLC system
consisted of a constaMetric 3200 solvent delivery system (LDC
Analytical, Riviera Beach, FL), a Waters 717plus autosampler
(Milford, MA) from which the sample tray was protected from
light, an Inertsil-ODS 80A analytical column (150  4.6 mm
internal diameter; 5-m particle size; Alltech Applied Sciences,
Breda, the Netherlands) maintained at 60°C by a model SpH99
column oven (Spark Holland, Meppel, the Netherlands), and a
Fig. 1 Chemical structures of lurtotecan and its photodegradant MEC.
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Jasco FP-920 fluorescence detector (Jasco, Maarssen, the Neth-
erlands) operating at excitation and emission wavelengths of
378 and 420 nm (40-nm band width), respectively. The mobile
phases consisted of 1 M ammonium acetate:water:ACN (1:6:3,
v/v/v), with the pH adjusted to 5.5, and the flow rate was set at
0.50 ml/min.
MEC was extracted from 50-l aliquots of heparinized
whole blood using 250 l of a mixture of MeOH:ACN (1:1, v/v)
in 1.5-ml polypropylene tubes (Eppendorf, Hamburg, Germa-
ny). The samples were vigorously vortex-mixed for 5 min on a
multitube vortex mixer, followed by centrifugation for 5 min at
23,000  g at ambient temperature. A volume of 150 l of the
clear supernatant was transferred to a new 1.5-ml polypropylene
tube, followed by addition of 250 l of 25 mM ammonium
acetate (pH 3.0). Subsequently, a volume of 300 l was trans-
ferred to a low-volume insert of glass, from which 200 l were
injected into the HPLC system. The calibration curves were
constructed in human heparinized whole blood in concentrations
of 0.10, 0.25, 1.00, 2.50, 5.0, and 10.0 ng/ml, by serial dilutions
in PBS of a MEC working solution containing 10 g/ml in
DMSO. Four pools of QC samples containing MEC were pre-
pared in heparinized whole blood at concentrations of 0.40,
4.00, 8.00, and 80.0 ng/ml MEC, by addition of appropriate
volumes of dilutions of MEC in PBS to whole blood. A fifth QC
sample containing 800 ng/ml NX 211 was also prepared in
heparinized whole blood to minimize potential differences with
clinical samples.
Validation of the assay included a set of calibration sam-
ples assayed in duplicate, with LLQ and QC samples in quin-
tuplicate, and was performed on four separate occasions. With-
in-run and between-run precisions were calculated by one-way
ANOVA for each concentration, using the run-day as variable.
The extraction recovery for MEC was calculated by comparing
peak heights obtained from processed samples containing 2.50
ng/ml MEC in PBS to those obtained in extracted calibration
samples.
Stability of NX 211. The increase of MEC in plasma and
whole blood containing NX 211 (800 ng/ml) was tested on three
separate occasions at ambient temperature, by placing 250-l
aliquots of the samples in the dark and in sodium light (lamp,
Philips SON-T-Plus 70 W), laboratory light (lamp, Philips TLD
36W), and in sunlight. After a 2-h incubation, 50-l aliquots
were stored in duplicate at 80°C until analysis. The plasma
and whole blood concentrations of MEC were determined using
the method described earlier and were compared with MEC
concentrations in nonincubated samples. The increase of MEC
in the extracts of the QC sample containing NX 211 (800 ng/ml)
was tested by placing the extracts on three separate occasions at
ambient temperature in laboratory and sodium light. After 1-
and 2-h incubation periods, the extracts were placed in the
autosampler, and peak heights were compared with those of
extracts stored in the dark. The light sensitivity of the clinical
formulation of NX 211 was tested by placing serial dilutions of
NX 211 in D5W in the dark and in sodium and laboratory light.
After 2 h, 50-l aliquots were stored in duplicate at 80°C and
were analyzed for MEC concentrations using the assay de-
scribed, within 1 week after the experiments. The concentrations
of MEC in the incubated samples were compared with nonin-
cubated serial dilutions of NX 211 in D5W.
To rule out a potential metabolic conversion of lurtotecan
into MEC, 1-ml aliquots (1 mg/ml) of pooled human liver
microsomes (Gentest, Woburn, MA) were incubated in the dark
in a phosphate buffer of pH 7.4 at 37°C with 2 M lurtotecan or
NX 211 in the presence of 3 M NADPH. After a 1-h incubation
period, 50-l aliquots were analyzed for MEC concentrations
resulting from metabolic instability, as described for whole
blood samples.
Clinical Samples. Whole blood samples for pharmaco-
kinetic analysis were drawn from a vein in the arm opposite to
that used for drug infusion from two male cancer patients (ages
39 and 64 years) participating in a Phase I trial (10) and
collected in 4.5-ml glass tubes containing lithium heparin as
anticoagulant. Samples were obtained before drug administra-
tion and at 0.5 (end of infusion), 1, 1.5, 2.5, 4, 6, 8, 24, 48, 72,
and 96 h after start of infusion and were immediately transferred
to a polypropylene vial and stored at 80°C. The NX 211 was
formulated as a sterile liposomal dispersion of lurtotecan in a
buffer composed of 10 mM ammonium chloride and 9% sucrose
and was supplied in 50-ml clear glass vials containing 5 mg of
the active agent. Each vial contained 80 mg of hydrogenated soy
phosphatidylcholine, 19 mg of cholesterol, 0.9 g of sucrose, 2
mg of citric acid, and 5 mg of ammonium chloride to a total
volume of 10 ml. Dose solutions for administration were pre-
pared in polyvinylchloride-free infusion syringes under aseptic
conditions by dilution of the pharmaceutical preparation with
D5W to a volume of 25 ml. The solution was delivered by a
30-min i.v. infusion and was protected from light by wrapping
the syringe in aluminum foil. Small aliquots of the NX 211
solutions were stored at 80°C for analysis of MEC and total
lurtotecan (11) concentrations. The current clinical protocol was
approved by the Rotterdam Cancer Institute Review Board, and
both patients signed informed consent before study entry.
RESULTS
Structural Identification. The principal unknown peak
observed in plasma samples of patients receiving NX 211 (11)
was prepared and isolated (0.6–0.7 mg) after irradiation of
lurtotecan and dried down to a pale-yellow powdery residue.
The purified compound yielded NMR spectra with the aromatic
part very similar to that of LRT (Ref. 14) [  0.87, t, 3H, J 
7.2 Hz, 19-CH3;   1.87, m, 2H, 18-CH2;   2.67, s, 3H,
B-ring CH3;   4.43, s, 4H, O-CH2-CH2-O;   5.22 and  
5.42, 2s, 22H, CH2s 5 and 17;   7.25, s, 1H, Ar-H;  
7.54, s, 1H, Ar-H;   7.59, s, 1H, Ar-H]. However, the eight
protons of the piperazino group on the B-ring at C-7 at  
2.40–2.65 (m) were absent in the isolated product. The signal at
  2.67 (s, 3H), characteristic of an n-methyl substituent,
suggested that scission of the piperazino group had occurred at
the N-C bond of the B-ring and thus could be assigned to MEC
(Fig. 1). Electrospray ion-trap mass spectrometric analysis also
already indicated the loss of the C-7 side chain of the lurtotecan
molecule [molecular ion at m/z 409 (parent minus C-7 chain)]
(Ref. 11). The chromatographic purity of the compound on the
reversed-phase system was found to be99% (data not shown).
In Vitro Cytotoxicity. The cytotoxic properties of MEC
relative to lurtotecan and several clinically important analogues
were assessed by exposure of each test compound to a panel of
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seven cell lines. Under the experimental conditions applied,
MEC was found to be a highly potent inhibitor of cell prolifer-
ation in all cell lines. Among the tested topoisomerase I inhib-
itors lurtotecan, topotecan, and SN-38, MEC was found to be the
most potent inhibitor of cell growth during a 5-day continuous
exposure (Table 1). On average, MEC was 3.4 0.88-fold more
potent than lurtotecan, 3.5  1.1-fold more potent than SN-38,
and 13 3.0-fold more potent than topotecan in the seven tested
cell lines.
Stability of NX 211. To gain insight into the degradation
kinetics of lurtotecan as a potential source of MEC formation,
experiments were conducted under various conditions and light
intensities. In plasma as well as in whole blood, MEC was
formed out of NX 211 when incubated for 2 h at ambient
temperature in sunlight with, respectively, a 99- and 4.5-fold
increase in MEC concentration as compared with samples stored
at 80°C (Fig. 2). Plasma samples placed under sodium light
and laboratory light also showed increased MEC concentrations,
whereas in blood no increase was observed under the same
conditions (Fig. 2). An increase in the concentration of MEC
also was found after incubation of blood extracts at ambient
temperature under sodium light and laboratory light (Fig. 2A).
Increased concentrations of MEC in the clinical formulation of
NX 211 were observed after a 2-h incubation at ambient tem-
perature under sodium and laboratory light. After dilution of this
clinical formulation in D5W, the light sensitivity of NX 211 was
increased (Fig. 2B). In addition, no increases in MEC concen-
trations were found after a 1-h incubation period of lurtotecan or
NX 211 in pooled human liver microsomes, suggesting that the
compound was not sensitive to hepatic metabolic degradation.
HPLC Analysis. To obtain information on the pharma-
cological and toxicological relevance of the lurtotecan photol-
ysis, we set out to develop an analytical method to allow
quantitative determination of MEC in samples of patients re-
ceiving NX 211 infusions. In view of the relative stability of
MEC in whole blood samples, we focused our attention on this
matrix to address the pharmacokinetic behavior of the com-
pound. The calibration curves of MEC in human heparinized
whole blood were linear over the studied range of 0.10–10
ng/ml, with Pearson’s regression coefficients ranging from
0.9986 to 0.9995 using weighted (1/[MEC]) linear least-squares
regression analysis. The retention time of MEC was 13 min
(overall run time, 15 min), and no endogenous interferences
were found in drug-free specimens (Fig. 3). The LLQ of the
method was established at 0.10 ng/ml (0.24 nM), and the
within- and between-run precisions of the LLQ and QC samples
were 7.8%, with the accuracy ranging from 98.4 to 104%
(Table 2). The within- and between-run precisions of the QC
sample containing 800 ng/ml NX 211 were 9.7 and 17%, re-
spectively. All of the QC samples were found to be stable during
Table 1 Comparative in vitro cytotoxicity of MEC and structural analogues
Cell line
MEC IC50
(nM)
Lurtotecan
IC50 (nM) Fa
SN-38 IC50
(nM) F
Topotecan
IC50 (nM) F
WIDr 2.4 0.035 7.6 1.8 3.1 8.0  0.87 3.3 27  1.9 11
IGROV-1 1.6 0.023 5.4 0.67 3.3 3.5 0.92 2.2 19 2.9 12
M19 25 2.1 80  65 3.2 117  96 4.6 271  185 11
H226 8.1 0.55 15  1.9 1.8 34  40 4.2 103  51 13
A498 3.3 0.17 13  11 4.0 8.5  1.4 2.6 32  7.7 9.7
MCF-7 1.3 0.022 4.3 1.63 3.5 3.5 0.80 2.8 19 4.3 15
EVSAT 8.1 0.58 38  30 4.7 41  31 5.0 147  46 18
a F, fold less toxic than MEC.
Fig. 2 Stability of lurtotecan in human whole blood and plasma with
added NX 211 (800 ng/ml), blood extracts (inset A), and aqueous
dilutions of NX 211 in D5W (inset B) expressed as fold increase in MEC
formation relative to a control sample (nominal) after a 2-h incubation
period. Data Represent Means (Bars)  SD (Error Bars). Columns,
various incubation/light intensity conditions: black, darkness; narrowly
hatched, sodium light; widely hatched, laboratory light; white, sunlight.
Fig. 3 Reversed-phase HPLC tracings of a blank whole blood extract
(A), a whole blood sample with added MEC (0.25 ng/ml; B), and a
whole blood sample with the clinical formulation of NX 211 added (800
ng/ml; C). I, MEC.
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three freeze-thaw cycles. The recovery of MEC was constant
over the entire range and was 104  11.9% (n  43). Overall,
these validation data of the assay were considered acceptable for
its use in clinical studies.
Patient Studies. The two studied patients received 7.5
and 7.3 mg of NX 211 (14.5 and 14.1 mol), respectively. The
total amount of lurtotecan in the infusion solutions of both
patients was established at 6.9 mg (13.2 mol). The total
amount of MEC in the sample taken before infusion of patient
1 was 30.1 g (73.5 nmol), whereas at the end of the infusion
the total amount of MEC was increased to 73.5 g (180 nmol).
Thus, the percentage of NX 211 administered as MEC, on a
molecular basis, was 0.56% before infusion and 1.4% at the end
of the infusion. From patient 2, a sample was taken before
infusion, which contained 75.7 g of MEC (185 nmol), i.e., at
least 1.4% of the total amount of drug administered was in the
form of MEC. The kinetic profiles of total lurtotecan and MEC
obtained from the two patients are shown in Fig. 4.
DISCUSSION
In the present study, we isolated submilligram quantities
(0.6–0.7 mg) of a (highly apolar) circulating compound present
in the plasma of patients treated with NX 211, a liposomal
preparation of the topoisomerase I inhibitor lurtotecan. Follow-
ing serial purification steps, the product was eventually obtained
as a pale yellow powdery residue, and the use of HPLC in
combination with fluorescence detection and NMR enabled us
to identify its chemical structure. NMR characteristics of the
aromatic part were shown to be very similar to that of lurtotecan,
and the isolated product was tentatively identified as MEC. This
structural assignment is in accordance with our earlier finding of
the loss of the C-7 side chain of the lurtotecan molecule using
electrospray ion-trap mass spectrometric analysis (11).
MEC was found to be a highly potent inhibitor of cell
growth in culture after a 5-day continuous exposure in a panel of
seven cell lines, with IC50s on average 3.4-, 3.5-, and 13-fold
lower than those of the parent drug lurtotecan, the irinotecan
metabolite SN-38, and topotecan, respectively. These data are
consistent with earlier findings of the substantially higher in
vitro cytotoxic activity of 7-methyl-10,11-methylenedioxy-
camptothecin compared with 10,11-methylenedioxy-camptoth-
ecin after a 3-day continuous exposure (15). The former com-
pound is chemically similar to MEC, with a methylenedioxy
substitution at the C10,11 positions in the core structure instead
of an ethylenedioxy moiety for MEC. The substitution of the
methyl moiety at the B-ring thus resulted in enhanced cytotox-
icity, which is in agreement with known structure-activity rela-
tionships of camptothecin analogues, indicating that alkylated
substitutions at C7 tend to increase topoisomerase I-inhibitory
activity and simultaneously decrease aqueous solubility (16).
Moreover, 7-chloromethyl-10,11-ethylenedioxy-camptothecin
was found recently to be a more potent inhibitor of cell growth
than lurtotecan and topotecan in several tumor cell lines during
a 48-h continuous exposure (14). In addition, this agent, which
has an additional Chloro substitution at the methyl moiety at the
B-ring relative to MEC, was almost insoluble in water, which is
also in agreement with the current findings.
MEC is most likely a product of lurtotecan photolysis
because the parent drug was highly sensitive to light-induced
degradation and was not significantly converted to MEC by
human liver microsomes. In aqueous solutions, the rate of
lurtotecan degradation appeared to be inversely proportional to
drug concentration and depended greatly on light intensity, with
no noticeable degradation occurring in the dark and progres-
sively increased instability in the presence of sodium light 	
laboratory light 	 sunlight. The lurtotecan degradation kinetics
in biological fluids was markedly altered, which is most likely
associated with stabilizing effects of matrix components, as has
been observed previously for anthracycline antineoplastic
agents (17). As outlined, such effects might be caused either by
increased drug stability attributable to binding to matrix constit-
uents, by quenching of incident light by intense coloring of the
sample, or by the presence of particulate matter (e.g., blood
cells). In contrast to the photodegradation of lurtotecan, photol-
ysis of irinotecan (CPT-11), one of the most extensively studied
camptothecin analogues, only occurs at the fragile lactone-ring
structure (18, 19). In view of the close chemical similarity of the
lactone moiety between camptothecins, photodegradation of
lurtotecan is also likely to occur at this site of the molecule. In
general, however, such degradation products are not of major
(clinical) interest, because the reactivity of an intact lactone-ring
structure is required for the generation of topoisomerase I-
Table 2 Validation characteristics of QC samples for the HPLC
assay of MEC
Nominal
(ng/ml)
Observed
(ng/ml)
WRPa
(%)
BRP
(%)
ACC
(%)
0.10b 0.10 7.1 2.7 104
0.40 0.40 7.8 c 101
4.00 4.01 3.4 6.0 100
8.00 8.23 6.0 c 103
80.0 78.7 3.9 7.5 98.4
800 NX 211 0.92 9.7 17
a WRP, within-run precision; BRP, between-run precision; ACC,
accuracy.
b LLQ samples.
c No additional variation was observed as a result of performing the
assay in different runs.
Fig. 4 In vivo pharmacokinetics of total lurtotecan (F, E) and MEC
(Œ, ‚) in whole blood of two patients treated with NX 211 [7.3 mg (E,
‚) and 7.5 mg (F, Œ)] administered as a 30-min i.v. infusion.
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mediated DNA cleavage and antitumor activity of all known
camptothecin analogues (20).
The question arises as to whether the additional chromato-
graphic peaks observed in the plasma samples of patients were
the result of photochemical degradation during the blood sample
handling and subsequent analytical procedure, or that MEC was
coadministered simultaneously with the NX 211 infusate. We
found that, in vitro, the amount of MEC in plasma samples
increased 99-, 16-, and 2.2-fold after a 2-h exposure to sunlight,
laboratory light, and sodium light, respectively, whereas after
incubation in the dark, no increase was observed. In contrast to
plasma, MEC concentrations did not increase in whole blood
under similar conditions, with the exception of sunlight expo-
sure, where incubation resulted in a 4.5-fold increase in MEC
concentration. Although it was beyond the scope of this study to
assess the chemical basis of this discrepant behavior, the appar-
ent stability of MEC in whole blood samples provided the
possibility to study its disposition in patients. The HPLC method
developed for this purpose was shown to be sufficiently accurate
and precise to monitor circulating concentrations in patients
treated with NX 211. On average, the total amount of MEC in
the samples with 800 ng/ml NX 211 added (1544 nM Lurtote-
can) was established at 0.92 ng/ml (2.25 nM). Hence, a small
fraction (0.15%) of the clinical formulation of NX 211 is thus
already present in the form of the photochemical degradant
MEC.
The lower percentages of MEC present in the blood sam-
ples of the two studied patients, ranging from 0.061 to 0.24%,
compared with values of 0.56–1.4% in the NX 211 infusates,
could be indicative for extraliposomal positioning of MEC. The
photostability data presented here also suggest that the infusates
are far more sensitive to production of MEC than whole blood
under laboratory conditions. Currently, we are conducting a
retrospective analysis of whole blood samples in a larger group
of cancer patients treated with NX 211 to describe in more detail
the pharmacokinetic behavior of MEC.
In conclusion, we have shown that lurtotecan in the NX
211 is sensitive to a rapid degradation if exposed to light,
resulting in formation of a highly cytotoxic compound that was
structurally identified as MEC. The data presented may be of
clinical importance because dilutions of NX 211 for use in
patients are prepared in aqueous solutions, usually in advance of
administrations, as 30-min i.v. infusions. Clearly, the presence
of this product at high enough concentrations not only could
confound in vitro and in vivo cytotoxicity and antitumor activity
studies but also might distress efforts to elucidate the metabolic
fate of lurtotecan and potentially other (new) camptothecin
derivatives. Procedures to minimize formation of MEC, by the
use of amber vials for NX 211 and by preparation of dilutions
immediately before clinical use in a fashion completely pro-
tected from any light, are currently being routinely imple-
mented.
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